Clinical Trial Detail

NCT ID NCT02574078
Title A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Crizotinib + Nivolumab

Erlotinib + Nivolumab

Nivolumab + Pemetrexed

Bevacizumab

Carboplatin + Pemetrexed

Bevacizumab + Nivolumab

Nivolumab

Erlotinib

Carboplatin + Paclitaxel

Carboplatin + Docetaxel

Carboplatin + Nab-paclitaxel

Carboplatin + Gemcitabine

Paclitaxel

Docetaxel

Pemetrexed

Gemcitabine

Age Groups: adult senior

No variant requirements are available.